Skip to main content
OpenTrials
Completed

NCT Number: NCT01501123

Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST)

* The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the sedation of agitated patients in the prehospital environment * The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1

o The RASS is a well validated standardized score to measure a patient's agitation * The secondary outcomes are

* Time until RASS returns to 0 or 1 if RASS <0 * Need for additional sedation * Adverse effects (need for intubation, arrhythmia) * Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying haloperidol * Identification of potential study patients will be per state protocols * Exclusion Criteria for the study * Age <18 * Pregnant * Allergic to study medication * Transport to hospital other than Mercy Fitzgerald Hospital * Unable to reach medical command prior to giving medication * When a paramedic identifies a possible study candidate, the paramedic will consult medical command to see if the patient is appropriate for the study * If the medical command agrees the patient is appropriate for the study, patients will be randomized to * Odd days: Haloperidol 5mg IM (age <65) or haloperidol 2.5 mg IM (age ≥65) * Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age <65) or maximum of 2.5mg (age ≥65) * The RASS will be documented by the prehospital providers every 5 minutes until arrival at the hospital * Once the patient arrives at the ED, the RASS will be documented in PICIS® by the emergency department nurse at the time of triage and at a minimum of hourly until the RASS =0 or 1 for 2 consecutive hours * Questions may be directed to Dr. Isenberg at [email protected] or at (267) 205-6453

Richmond Agitation Sedation Scale

RASS RASS Description

* 4 Combative, violent, danger to staff * 3 Pulls or removes tube(s) or catheters; aggressive * 2 Frequent non-purposeful movement * 1 Anxious, apprehensive, but not aggressive 0 Alert and calm

* 1 Awakens to voice (eye opening/contact) >10 sec * 2 Light sedation, briefly awakens to voice (eye opening/contact) <10 sec * 3 Moderate sedation, movement or eye opening. No eye contact * 4 Deep sedation, no response to voice, but movement or eye opening to physical stimulation * 5 Unarousable, no response to voice or physical stimulation

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mercy Catholic Medical Center

Darby, Pennsylvania, 19023, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Exclusion criteria

  • Age <18
  • Pregnant
  • Allergic to study medication
  • Transport to hospital other than Mercy Fitzgerald Hospital
  • Unable to reach medical command prior to giving medication

Treatment and study plan

Haloperidol

Drug

5mg IM

midazolam

Drug

IM midazolam

Primary outcomes

  1. Time to sedation

    Time frame: 10 minutes

Sponsors and collaborators

Lead sponsor

Catholic Health East

Other

Registry information

Official study title

Re-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

Acronym: PHAST

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Dec 29, 2011
Registry last updated
Jul 24, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.